Literature DB >> 744010

Monodeiodination of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine to 3,3'-diiodothyronine in vitro.

I J Chopra, S Y Wu, Y Nakamura, D H Solomon.   

Abstract

To study conversion of 3,5,3'-triiodothyroinine (T3) and 3,3',5'-triiodothyronine (rT3) to 3,3'-diiodothyronine (T2) in vitro, T3 or rT3 was incubated at pH 7.35 with homogenates of several rat tissues (liver, kidney, muscle, heart, ling, spleen, intestines, and brain) for 15 min at 37 C. The T2 generated during incubation was measured in an ethanol extract of the incubation mixture by a specific RIA of T2; T4, T3, and rT3 cross-reacted in the T2 RIA only to an extent of 0.006, 0.2, and 0.04%, respectively. T2 was produced regularly when T3 or rT3 was incubated with liver or kidney homogenates; other tissues generated little or no T2 under similar conditions. Studies with liver homogenates revealed that production of T2 from both T3 and rT3 was influenced significantly by tissue and substrate concentractions, temperature, pH and duration of incubation. T3- as well as rT3-monodeiodinating activities were unaffected by large doses (greater than or equal to 3 micrometer) of sodium iodide, diiodotyrosine, and methimazole, but were inhibited in a dose-dependent manner by propylthiouracil, iodiacetic acid, and dinitrophenol. The apparent Km for conversion of T3 to T2 approximated 6.0 micrometer and that for conversion of rT3 to T2' 65 nM. Propylthiouracil and iodoacetic acid inhibited conversion of both T3 and rT3 to T2 in an uncompetititve and a non-competitive manner, respectively. The various data suggest that 1) monodeiodination of T3 and rT3 to T2 is enzymic in nature; 2) liver and kidney may be the major sites of metabolic transformations of T3 and rT3 to T2.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 744010     DOI: 10.1210/endo-102-4-1099

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

Review 1.  Hormonal changes in non-endocrine disease.

Authors:  C G Semple
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

2.  Kinetics of enzymic reductive deiodination of iodothyronines. Effect of pH.

Authors:  T J Visser; D Fekkes; R Docter; G Hennemann
Journal:  Biochem J       Date:  1979-06-01       Impact factor: 3.857

3.  Iodothyronine 5'-deiodinase in rat kidney microsomes. Kinetic behavior at low substrate concentrations.

Authors:  A Goswami; I N Rosenberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

4.  Phenolic and tyrosyl ring deiodination of iodothyronines in rat brain homogenates.

Authors:  M M Kaplan; K A Yaskoski
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

5.  Binding of radioiodinated propylthiouracil to rat liver microsomal fractions. Stimulation by substrates for iodothyronine 5'-deiodinase.

Authors:  T J Visser; E Van Overmeeren
Journal:  Biochem J       Date:  1979-10-01       Impact factor: 3.857

6.  Evidence for a single enzyme in rat liver catalysing the deiodination of the tyrosyl and the phenolic ring of iodothyronines.

Authors:  D Fekkes; G Hennemann; T J Visser
Journal:  Biochem J       Date:  1982-03-01       Impact factor: 3.857

7.  Correlation between antithyroid effect and serum concentrations of propylthiouracil in patients with hyperthyroidism.

Authors:  J P Kampmann; J E Mølholm Hansen
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  Inhibition of peripheral deiodination of 3, 5, 3'-triiodothyronine: an adverse effect of propylthiouracil in the treatment of T3-thyrotoxicosis.

Authors:  E Heinen; J Herrmann; D Mosny; F Moreno; R Teschke; H L Krüskemper
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

10.  Hepatic extraction and renal production of 3,3'-diiodothyronine and 3',5'-diiodothyronine in man.

Authors:  J Faber; O K Faber; B Lund; C Kirkegaard; J Wahren
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.